On November 9, Mitsui Chemicals signed a share transfer agreement to acquire semiconductor materials leader JSR from funds managed by JIC Capital, a unit of the public-private fund Japan Investment Corporation (JIC). The transaction value is ¥1.84 trillion. Mitsui Chemicals will carry out the all-cash acquisition together with the Development Bank of Japan (DBJ), aiming to close in the second half of fiscal 2027. The price is about 29.5 times JSR's latest consolidated core operating profit, and the company plans to fund about 89% of the required capital with a bridge loan. Even adding the roughly ¥40 billion in annual incremental profit that Mitsui Chemicals targets by fiscal 2035, the price comes to about 18 times combined profit. Given the heavy financial burden after the deal, the equity-credit financing of roughly ¥300 billion that the company plans to consider within a year of closing looks set to be a key indicator of whether the plan is workable.
¥1.84 trillion price tag is about 2.3 times Mitsui Chemicals' market capitalization
According to Mitsui Chemicals' timely disclosure, the ¥1.84 trillion transaction value consists of ¥1,392.1 billion in equity value and ¥447.9 billion in interest-bearing debt and other items. Of the equity value, ¥200 billion is expected to be funded by DBJ, and the final consideration will be set after adjustments at closing. Mitsui Chemicals expects to acquire all of the JSR common shares held by the two funds managed by JIC Capital. It also plans to acquire the Class A and Class B preferred shares held by Mizuho Bank and DBJ at the same time as the closing.
On November 4, Reuters reported that JIC planned to sell JSR to Mitsui Chemicals and that the deal could be worth more than ¥1.3 trillion. The price now announced is consistent with that earlier report. However, because the ¥1.84 trillion includes ¥447.9 billion in interest-bearing debt and other items, it needs to be distinguished from the equity value of ¥1,392.1 billion.
Another notable feature is how large the price is relative to the buyer's size. According to Reuters' November 4 report, Mitsui Chemicals then had a market capitalization of about ¥800 billion, cash on hand of ¥217.8 billion at the end of June 2026, and interest-bearing debt of ¥876.4 billion. The ¥1.84 trillion price is about 2.3 times the market capitalization at the time of that report. Market capitalization moves with the share price, however, and Finimize reported that Mitsui Chemicals' shares fell 13% the same day, so that multiple is not fixed. Kyodo News described the deal as the largest in Japan's domestic chemical industry.
Mitsui Chemicals plans to position JSR as a core business in its ICT solutions area. It says that combining the two companies' businesses will create one of Japan's largest semiconductor materials makers by sales. It expects the impact on results for the fiscal year ending March 2027 to be minor.
About 29.5 times core operating profit, and the financing plan behind the deal
For the fiscal year ended March 2026, JSR reported revenue of ¥440.7 billion, consolidated core operating profit of ¥62.3 billion, and operating profit of ¥40.5 billion. Dividing the ¥1.84 trillion price by consolidated core operating profit gives about 29.5 times, and by operating profit about 45 times. Consolidated core operating profit is JSR's own profit measure, which adds back to operating profit the amortization from the purchase price allocation (PPA) that arose when the company took the former JSR private. Because the price includes interest-bearing debt and other items, these multiples differ from an ordinary price-earnings ratio (PER) and serve only as a guide to compare deal size with earning power.
Mitsui Chemicals has set a goal of generating about ¥40 billion in annual incremental profit through business integration by fiscal 2035. Simply adding that ¥40 billion to JSR's ¥62.3 billion in core operating profit gives ¥102.3 billion. The ¥1.84 trillion price is about 18 times that figure, meaning that even if the planned profit increase is fully realized, the price-to-profit multiple does not fall to a single digit.
The financing plan is also large. Mitsui Chemicals plans to fund the acquisition with a ¥1.64 trillion bridge loan from its main banks and a ¥200 billion investment from DBJ. Of the ¥1.84 trillion total, the bridge loan accounts for about 89.1%. Mitsui Chemicals has said that the acquisition will temporarily push its Net Debt/EBITDA ratio (net interest-bearing debt divided by earnings before interest, taxes, depreciation and amortization) above 4x, and that its net D/E ratio and equity ratio are also expected to worsen.
A bridge loan is short-term interim financing used until longer-term funding is in place. How the company refinances the huge borrowing and stabilizes its financial base therefore matters. To keep its issuer rating in the A range, Mitsui Chemicals is considering raising funds equivalent to ¥300 billion in rating-agency equity credit within about a year of closing.
Specifically, the plan envisions raising up to ¥150 billion through common shares, including the use of treasury shares, and ¥300 billion through mezzanine financing. Mezzanine financing is a funding method with characteristics between equity such as common shares and ordinary debt such as loans. Under the plan, 50% of the mezzanine amount is assumed to be treated as equity by rating agencies. The ¥150 billion in common shares plus ¥150 billion, half of the ¥300 billion mezzanine, would secure ¥300 billion in equity credit. The company plans to raise the remaining required funds with debt-type financing.
This ¥300 billion in equity credit equals about 18.3% of the ¥1.64 trillion bridge loan. It is, however, a comparison between the rating-based equity credit and the size of the bridge loan, and does not mean that 18.3% of the bridge loan will simply be repaid. DBJ's ¥200 billion investment is also not included in the denominator of this comparison. Note as well that the planned common share and mezzanine financing could total up to ¥450 billion, but not all of it would be recognized as equity by rating agencies.
The shelf registration for common shares, with a ceiling of ¥150 billion, was filed on November 9 and is scheduled to take effect on November 17. The issuance period runs for two years through November 16, 2028. Based on the roughly ¥800 billion market capitalization cited in Reuters' November 4 report, this ceiling equals a little under 20%. It does not directly represent the dilution rate from actual share issuance, but it is a significant size for existing shareholders weighing the impact of future capital raising on share value.
Can JSR's profit recovery justify the burden?
In evaluating the deal, the rapid recovery in JSR's earning power cannot be overlooked. JSR's consolidated core operating profit improved from a ¥1.6 billion loss in the fiscal year ended March 2025 to a ¥62.3 billion profit in the fiscal year ended March 2026. Revenue also rose 13.4% from ¥388.8 billion to ¥440.7 billion, showing a strong rebound. If the recovery continues, one could argue that the roughly 29.5x multiple, calculated on current profit levels, only looks expensive relative to future earning power.
The ¥40 billion in annual incremental profit targeted by Mitsui Chemicals is also an important factor in judging the deal's value. Separately from that profit increase, the company expects effects worth more than ¥350 billion in business value from improved capital efficiency, including moves toward an asset-light model, and from measures at JSR. Reuters also reported that, with investment in data centers for generative AI continuing at a high level, there is a persistent view that semiconductor materials makers have significant room to grow. If such demand expansion continues, JSR's earning power could rise further.
Still, the profit recovery alone does not make the financial burden of the acquisition negligible. Even factoring in the full planned ¥40 billion in incremental annual profit, the price equals about 18 times combined profit. Mitsui Chemicals itself has also disclosed that its Net Debt/EBITDA ratio is expected to temporarily exceed 4x after closing. Even if earnings keep improving, delays in refinancing the bridge loan or raising equity-type funds could prolong the financial strain.
In addition, the ¥40 billion in annual incremental profit is a target for fiscal 2035, not profit available at the time of closing, planned for the second half of fiscal 2027. Inpria, which develops metal resist for EUV, one of the growth areas JSR highlights, posted an operating loss of $42.3 million on revenue of $60.06 million in fiscal 2025. Even businesses with expected future growth can face profitability challenges at present. JSR is also reported to regard its life sciences business as non-core and to continue considering all options for it. Whether such restructuring of the business portfolio leads to the planned profit increase and improved capital efficiency will also matter.
The focus now is whether Mitsui Chemicals can carry out, as planned, the ¥300 billion in equity-credit financing it aims to complete within about a year of closing, and improve its weakened financial indicators. If it completes the necessary capital raising within that period and Net Debt/EBITDA also falls below 4x, concerns about the financial burden would ease to some extent. Conversely, if the financing is delayed or falls short of the plan, the financial risks of the huge acquisition would come into sharper focus. The 4x level is, however, a temporary projection for just after closing, and the final assessment will also need to consider the recovery in earning power and progress in reducing debt.
The deadline for raising capital also deserves attention. If closing occurs on or after November 17, 2027, the one-year mark after closing would fall after the current shelf registration expiry of November 16, 2028. That makes it worth watching whether the common share financing is carried out within the deadline, and whether the shelf registration is renewed if necessary. Going forward, it will be necessary to follow not only Mitsui Chemicals' quarterly results but also the status of share issuance under the shelf registration and how the mezzanine financing takes concrete shape.
On the business side, Mitsui Chemicals has said it will make mutual use of both companies' customer bases and product lines: Mitsui Pellicle and advanced photoresists for front-end processes, and ICROS Tape and thick-film resists for back-end processes. By handling a broad range of materials from front-end to back-end semiconductor manufacturing, it aims to strengthen the competitiveness of its business. Whether the broader product lineup translates into actual profit growth, however, will depend on progress in business integration and earnings improvement. In judging the success of the ¥1.84 trillion acquisition, the capital raising within a year of closing and the improvement in financial indicators will be an important first test, alongside the growth prospects of the semiconductor materials market.